K07.6
Conditions
Interventions
Group 1: Participants diagnosed with TMD: After a conventional impression was taken from Group 1 and a splint was fabricated from it, the first measurement for Group 1 is taken one week before the 3D-
Sponsors
Universitätsklinikum Erlangen, Zahnklinik 2, Zahnärztliche Prothetik
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • Age: Age of majority • Confirmed diagnosis of TMD (for groups 1 &2 • Good general condition • Signed consent form and consent under data protection law
Exclusion criteria
Exclusion criteria: • Age under 18 years • Wearing a total or partial denture • Systemic, neuromuscular, rheumatic, cardiovascular, metabolic, respiratory, acutely inflammatory or infectious diseases • Pregnancy • People with pacemakers, severe bronchial asthma or COPD • Splint therapy that has already taken place in the dental clinic of Erlangen • Medications with potential impact on HRV • Acute/past injuries in the face/jaw area with potential influence on splint therapy • Residence with significant geographical distance • People without a smartphone
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Answering the current questions of the influence of splint therapy on heart rate variability in TMD. During TMD therapy, HRV is measured using an HRV measuring device to draw conclusions about the success of TMD therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints include changes in clinical functional assessment and subject-reported symptom improvement. | — |
Countries
Germany
Contacts
Public ContactRagai Matta
Universitätsklinikum Erlangen, Zahnklinik 2, Zahnärztliche Prothetik
Outcome results
None listed